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THICK AS THIEVES? BIG PHARMA WIELDS ITS POWER
WITH THE HELP OF GOVERNMENT REGULATION †
Leslie E. Sekerka ∗
Lauren Benishek ∗∗
INTRODUCTION
Americans are barraged by an endless flow of ads that claim to remedy
medical maladies with prescribed drugs. The commercials depict productive
and happy lives, with suggestive associations that human flourishing can be
achieved via pharmaceutical intervention. The appeals are accompanied by an
exhaustive inventory of potentially negative life-altering side effects. As ads
end with this depiction of relational bliss through drug use, viewers hear a fastpaced listing of monotone non-segmented disclaimers, which can range from
modest impacts (e.g., slight weight gain) to very serious implications (e.g.,
suicidal ideations). Research suggests that hearing about the risks of use may
increase consumers’ trust in the advertising. 1 Sufferers may also conclude that
stronger means better (i.e., helping them more effectively manage their
condition). 2 Patients may prefer a name-brand drug because the medicine may
have a higher perceived quality due to advertising and promotional activities. 3
American consumers are enculturated to reinforce their desire for convenience
and accessibility, while also wanting their pains to go away. Moreover, they
†
Portions of this article originally appeared in: Leslie Sekerka, Debra Comer & Lauren Benishek, The
Inordinate Power of Big Pharma, in BUSINESS ETHICS: BEST PRACTICES FOR DESIGNING AND MANAGING
ETHICAL ORGANIZATIONS 355 (Denis Collins ed., 2018).
∗
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1
Amanda L. Connors, Comment, Big Bad Pharma: An Ethical Analysis of Physician-Directed and
Consumer-Directed Marketing Tactics, 73.1 ALB. L. REV. 243 (2009).
2
See also Joanne Kaufman, Think You’re Seeing More Drugs Ads on TV? You Are, and Here’s Why,
N.Y. TIMES, Dec. 24, 2017, https://www.nytimes.com/2017/12/24/business/media/prescription-drugsadvertising-tv.html.
3
Kathleen Iacocca, James Sawhill & Yao Zhao, Why Brand Drugs Priced Higher Than Generic
Equivalents, 9 INT’L J. PHARM. & HEALTHCARE MKTG. 3 (2015).
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expect to view ads that compel them to want novel products or new
applications. When it comes to health, consumers tend to mitigate the risk of
taking drugs. 4 Cognitive dissonance fuels a process of rationalizing side effects
as part of the cost of wellbeing. 5
Direct-to-consumer pharmaceutical advertising (DTCPA) refers to any
promotional effort by a pharmaceutical company to present pharmaceutical
drug information to the public in the lay media. 6 Drug companies claim the ads
are designed to educate patients, encourage doctor-patient dialogue, and move
people to take more responsibility for their healthcare. 7 Opponents suggest that
this type of marketing tends to normalize obscure disorders, encourages people
to believe they suffer from certain dysfunctions, and prompts framing
uncommon diseases in a normal light. 8 When pharmaceutical firms get U.S.
Federal Drug Administration (FDA) approval for a new product, under the
auspices of health communication, the government enables them to market the
drug and create demand where none previously existed.

4
Ho-Young Ahn et al., Consumers’ Optimism Bias and Responses to Risk Disclosures in Direct-toConsumer (DTC) Prescription Drug Advertising: The Moderating Role of Subjective Health Literacy, 48 J.
CONSUMER AFFAIRS 175 (2014).
5
Johanna Jarcho et al., The Neural Basis Rationalization: Cognitive Dissonance Reduction during
Decision Making, SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE, no. 6.4, 2011, at 460-67.
6
Billion Dollar Pills, ECONOMIST (Jan. 25, 2007), https://www.economist.com/node/8585891 (in
America, direct-to-consumer drug advertising has increased from spending of $1.1 billion in 1997 to $4.5
billion in 2006); The Impact of Direct-to-Consumer Advertising, U.S. FOOD AND DRUG ADMIN.,
https://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143562.htm (last visited Mar. 20, 2018).
7
Editorial, Turn the Volume Down on Drug Ads, N.Y. TIMES (Nov. 27, 2015), https://www.nytimes.
com/2015/11/27/opinion/turn-the-volume-down-on-drug-ads.html.
8
Michael Wilkes et al., Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and
Implications, 2000 HEALTH AFF. 19(2) at 110, 112.; Martin Hirsch (2008). Side effects of corporate greed:
Pharmaceutical companies need a dose of corporate social responsibility. 9 MINN. J. L., SCI. & TECH. 607
(2008).
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Table 1. Top U.S. Drug Advertisement Expenditures (2016) 9

Drug/Maker

Advertisement
(in USD millions)

Purpose

Humira/AbbVie

$439

Anti-inflammatory

Lyrica/Pfizer

$392

Nerve pain
management

Eliquis/Bristol-Myers
Squibb

$296

Blood thinner

Xeljanz/Pfizer

$258

Anti-inflammatory

Opdivo/Bristol-Myers
Squibb

$168

Cancer treatment

Chantix/Pfizer

$151

Smoking cessation

Cialis/Lilly

$150

Erectile dysfunction

Trulicity/Lilly

$142

Increase glucose
(diabetes)

Prevnar/Pfizer

$142

Pneumonia vaccine

The pharmaceutical industry spends hundreds of millions of dollars
annually to market its products. Direct-to-consumer prescription ads are the
second-fastest growing ad category, competing with other top marketers
stemming from automotive, fast food, insurance, and cable/wireless
providers. 10,11 Ad spending for television by pharmaceutical companies has
more than doubled in the last four years, representing a 65% increase in this
genre since 2012. It is currently the seventh largest ad category in the U.S.,

9
Jon Swallen, Drug Advertising Booms to $6.4 Billion, KANTAR (May 8, 2017, 4:00 PM),
http://us.kantar.com/business/health/2017/drug-advertising-booms/.
10
Rachel Kornfield et al., Trends in Exposure to Televised Prescription Drug Advertising, 2003–2011,
48 AM. J. PREVENTIVE MEDICINE 5 (May 2015).
11
Bruce Horovitz & Julie Appleby, Prescription drug costs are up; So are TV ads promoting them,
USA TODAY (Mar. 16, 2017, 7:04 AM), https://www.usatoday.com/story/money/2017/03/16/prescriptiondrug-costs-up-tv-ads/99203878/.
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investing $6.4 billion in 2016. 12 Table 1 offers examples of top U.S. drug
advertisement expenditures in 2016. 13 Yet, greater ad spending does not
necessarily correlate with product effectiveness. One of the most advertised
drugs in 2016, Jublia (a toe fungus treatment), 14 costs about $600 a bottle but
is reported to work in fewer than 20% of users. 15
In 2016, 80 prescription drug advertisements were televised every hour,
totaling 1,920 drug ads directed at American viewers per day. 16 Television
networks—ABC, CBS, NBC—along with cable channels like CNN draw
millions of dollars from pharmaceutical advertising, approximately 8% of their
ad revenue. 17 Given U.S. viewers watch about five hours of television daily, 18
many citizens are likely to spend more time listening to pharmaceutical
advertisements than talking with their physician (typically 15 minutes per visit,
four times a year). 19,20,21
All this advertising can increase the cost of prescription drugs. 22 Ironically,
these ads actually serve as tax deductions for pharmaceutical firms. 23
Legislation to eliminate this deduction is currently being debated in the U.S.
Congress but powerful lobby groups backed by the industry are challenging

12
Jon Swallen, Drug Advertising Booms to $6.4 Billion, KANTAR (May 8, 2017, 4:00 PM),
http://us.kantar.com/business/health/2017/drug-advertising-booms/.
13
Id.
14
Aimee Picchi, Drug ads: $5.2 billion annually—and rising, CBS NEWS: MONEYWATCH (Mar. 11,
2016, 3:25 PM), https://www.cbsnews.com/news/drug-ads-5-2-billion-annually-and-rising/.
15
Treating Toenail Fungus, CONSUMER REPORTS (Jan. 7, 2016), https://www.consumerreports.org/
health/treating-toenail-fungus/.
16
Alix Spiegel, Selling Sickness: How Drug Ads Changed Healthcare, NPR (Oct. 13, 2009),
http://www.npr.org/templates/story/story.php?storyId=113675737.
17
Horovitz, supra note 10.
18
John Koblin, How Much Do We Love TV? Let Us Count the Ways, N.Y. TIMES (June 30, 2016),
https://www.nytimes.com/2016/07/01/business/media/nielsen-survey-media-viewing.html.
19
Carol Peckham, Medscape Physician Compensation Report 2016, MEDSCAPE (Apr. 1, 2016),
http://www.medscape.com/features/slideshow/compensation/2016/public/overview?src=wnl_physrep_160401
_mscpedit&uac=232148CZ&impID=1045700&faf=1#page=26.
20
Tim Mackey & Bryan Liang, It’s Time to Shine the Light on Direct-to-Consumer Advertising, 13
ANNALS FAMILY MEDICINE 82 (2015).
21
Niall McCarthy, Americans Visit Their Doctor 4 Times A Year. People In Japan Visit 13 Times A
Year [infographic], FORBES (Sep. 4, 2014, 8:47 AM), https://www.forbes.com/sites/niallmccarthy/2014/09/04/
americans-visit-their-doctor-4-times-a-year-people-in-japan-visit-13-times-a-yearinfographic/#35107e87e347/.
22
Thomas Dibacco, Just say no to drug ads on TV, WASH. TIMES (Feb. 8, 2017),
https://www.washingtontimes.com/news/2017/feb/8/drug-ads-on-tv-should-be-banned/.
23
Insideradio, Tax bill targets big pharma advertising deductions. (March 13, 2018), http://www.
insideradio.com/free/tax-bill-targets-big-pharma-advertising-deductions/article_5db46c5a-2685-11e8-bb4e1ba75015db76.html.
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these reforms with tenacious veracity. 24 To better understand the
interconnections between the U.S. government and the pharmaceutical
industry, it is important to explain the industry’s historical context. From there,
issues can be discussed and ideas for systemic change considered.
I.

THE GENESIS OF BIG PHARMA

To understand what drives these ads, it is necessary to examine the trilliondollar pharmaceutical industry known as Big Pharma. Big Pharma is the name
ascribed to a consortium of the world’s largest drug companies. The term is
applied to the vast and influential pharmaceutical industry and its trade group
in the U.S., known as the Pharmaceutical Research and Manufacturers of
America (PhRMA). Given the astronomical amount of money made in the
global prescription drug business, the industry has inordinate power and
influence over consumers’ lives. It is no surprise, then, that Big Pharma is the
subject of heated debate amongst many stakeholder groups. 25
Drug companies like Merck, Eli Lilly, and Roche; and chemical firms like
Bayer, ICI, Pfizer, and Sandoz, have been in business for more than 100 years,
going back to a time when most medicines were sold without prescriptions and
roughly half were provided by local druggists. The period between 1918 and
1939 was marked by the discovery and modest production of penicillin and
insulin. 26 As demand for analgesics and antibiotics escalated during World
War II, a government-supported international collaboration, including Merck,
Pfizer, Squibb, and Lilly, sought to mass produce penicillin. 27 The
unprecedented success of this effort signaled a new direction for drug
development involving collaboration between companies and the government,
forecasting the advent of the modern pharma industry.
The implementation of state healthcare systems in the post-war period
created a more stable market for prescribing and reimbursement processes. For
example, in 1957 the UK established a pricing scheme that enabled reasonable

24
Beth Bulick, Tax bill may target pharma’s DTC deduction, but ad industry’s ready to defend it,
FIERCEPHARMA (Dec. 11, 2017, 8:06 AM), https://www.fiercepharma.com/marketing/tax-bill-may-look-todeny-pharma-advertising-deduction-but-ad-association-ready-to-defend.
25
See generally MARCIA ANGELL, THE TRUTH ABOUT THE DRUG COMPANIES: HOW THEY DECEIVE US
AND WHAT TO DO ABOUT IT (Random House, reprt. ed. 2005).
26
David Taylor, The Pharmaceutical Industry and the Future of Drug Development, 41
PHARMACEUTICALS IN THE ENVIRONMENT 1 (R. Hester & R. Harrison eds., 2015).
27
Discovery and Development of Penicillin, AM. CHEMICAL SOC. INT’L HISTORIC CHEMICAL
LANDMARKS, https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html
(last visited Apr. 13, 2018).
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investment returns and incentivized commercial investment in the research and
manufacture of new products. 28 In the ensuing years, consumers benefited
from the introduction of over-the-counter products like acetaminophen and
ibuprofen, complemented by completely new classes of pharmaceuticals such
as oral contraceptives, betablockers, ACE inhibitors, benzodiazepines, and a
range of cancer treatments. 29
Between 1980–2000, drug development was largely in the hands of
multinationals, prompting the creation of “blockbuster drugs.” These chemical
compounds were designed to become consumer staples as treatments for
common, chronic ailments. For example, the ulcer medication Tagamet
quickly reached $1 billion in sales, followed by a succession of other
blockbusters like Eli Lilly’s Prozac (the first serotonin reuptake inhibitor) and
Astra’s Omeprazole (the first proton pump inhibitor). Pfizer’s cholesterol drug
Lipitor became the best-selling drug of all time, with $125 billion in sales over
15 years. Pharmaceuticals strategically promote products expected to become
the most profitable. For example, in 2011 Boehringer Ingelheim spent $464
million advertising its blood thinner Pradaxa. The investment appears to have
paid off: the drug passed the $1 billion sales mark the following year.
Today, prescription drugs are a massive market. Americans spent $325
billion in 2015 (equating to 1.8% of GDP and 10% of total national health
expenditures) on retail prescriptions alone (not including drugs administered
directly by healthcare providers). 30 Critics are concerned that pharmaceutical
firms are driven more by financial self-interest than by their espoused values to
serve society. Given today’s legal environment, this industry is expected to
reach $5.7 trillion by 2026, representing a 5/5% growth rate per year (20172026). 31 Pharmaceuticals have an especially robust duty to society because
they have the power to contribute to or deny the ability to live a healthy life.

28
Lesley Hannah & Jessica Phillips, Is the Current UK System of Pharmaceutical Price Regulation
Working?, LEXOLOGY (Feb. 20, 2017), https://www.lexology.com/library/detail.aspx?g=4f3f95a6-a667-4d6da113-09ec8a094cdd.
29
DAVID TAYLOR, The Pharmaceutical Industry and the Future of Drug Development, in
PHARMACEUTICALS IN THE ENVIRONMENT (VOL. 41) (R. Hester & R. Harrison eds., 2015).
30
Peter Olson & Louise Sheiner, The Hutchins Center Explains: Prescription Drug Spending,
BROOKINGS (Apr. 26, 2017), https://www.brookings.edu/blog/up-front/2017/04/26/the-hutchins-centerexplains-prescription-drug-spending/.
31
National Health Expenditure Projections 2017–2026: Forecast Summary, CTRS. FOR MEDICARE &
MEDICAID SERVS. (2018), https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-andReports/NationalHealthExpendData/Downloads/ForecastSummary.pdf.
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DIRECT-TO-CONSUMER PHARMACEUTICAL ADS

Ventola’s research provides historical context for DTCPA practices
today. 32 The Division of Drug Marketing, Advertising, and Communications
(DDMAC) within the FDA is responsible for DTCPA’s regulation. 33 The FDA
was given authority to approve pharmaceutical products for marketing in the
U.S., as a result of the Federal Food, Drug, and Cosmetic Act, passed in
1938. 34 In 1962, the FDA was afforded statutory authority to regulate
prescription drug labeling and advertising. Most recently, in 1969, the FDA
stipulated that pharmaceutical ads must (1) not be false or misleading, (2)
fairly represent a drugs risks and benefits, (3) include facts that are “material”
to the product’s advertised uses, and (4) briefly summarize every risk
described in the product’s labeling. 35 During the 1980s, the political climate
became more favorable to the pharmaceutical industry. Patients also became
more active participants in their medical decision-making, interacting with
their healthcare providers.
With television introducing DTCPAs, the FDA had to consider new
questions about how consumer drug advertising should be regulated. 36 In 1983,
the FDA imposed a voluntary moratorium, requesting that pharmaceutical
firms sustain from DTCPA while the agency studied the issue. 37 In 1985, the
FDA published a notice in the Federal Register claiming regulatory
jurisdiction over DTCPA, affirming that the prior standards of “fair balance”
and “brief summary”, were sufficient to protect American consumers against
deceptive or misleading claims. 38 Including additional information was
deemed costly and time prohibitive by pharmaceutical firms. As a result, ads
ultimately ended up being largely geared to encourage help-seeking, rather
than making direct product claims. Providing medical information to patients
via DTCPA’s presumably empowers them to discuss these treatments with
their providers.

32
C. Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 PHARMACY
& THERAPEUTICS 669 (Oct. 2011).
33
Id.; see also Connors, supra at note 23.
34
William Boden & George Diamond, DTCA for PTCA – Crossing the Line in Consumer Health
Education?, 358 NEW ENG. J. MED. 2197 (May 2008).
35
Id.
36
See Jeremy Greene & David Herzberg, HIDDEN in PLAIN SIGHT Marketing Prescription Drugs to
Consumers in the Twentieth Century, 100 AM. J. PUB. HEALTH 793 (May 2010).
37
Id.
38
Id.
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Twelve years later, after a hearing in 1995, the FDA issued a draft
guidance (with final regulations in 1999), explaining that advertisers had to
include only “major risks” and provide an “adequate provision” that would
direct viewers elsewhere to access complete “brief summary” information
elsewhere (via a toll-free number, a healthcare provider, website, etc.). 39 In
1997, advertising of prescription drugs and medical devices was legalized. The
FDA further relaxed the regulations in 2004, eliminating complete prescribing
information in print product claim ads and allowing the inclusion of a
simplified brief summary instead. 40 At this point, pharmaceutical companies
only had to provide information on “major risks” and provide simplified
language (i.e., easier for the average consumer to understand). 41
The FDA continues to regulate DTCPA, but critics say that now rules are
too relaxed and inadequately enforced. 42 Scholars writing for the New England
Journal of Medicine suggest that DTCPA increases pharmaceutical sales by
wielding a double-edged sword. The ads can simultaneously avert underuse,
but also contribute to potential overuse. 43 Serious concerns were expressed and
DTCPAs received increased attention when some very heavily advertised
drugs were suddenly removed from the market, after finding that they carried
serious risks. In 2015, the American Medical Association (AMA) voted that
the U.S. government should impose a ban on this practice. And yet, DTCPAs
continue to appear with disturbing regularity. The U.S. and New Zealand
remain the only two countries that permit these types of advertisements. 44 It is
therefore no coincidence that citizens of only two countries take an average of
more than two prescription medications regularly: the U.S. and New Zealand. 45
The USFDA, the agency responsible for pharmaceutical regulation, has
done little to address the AMA’s concern that these ads prompt consumers to
seek inappropriate drugs and to believe that there is a pill for every ill, even for

39

Gregory Abel et al., Direct-to-Consumer Advertising in Oncology, 11 ONCOLOGIST 217 (2006).
Amy Shaw, Direct-to-Consumer Advertising (DTC) of Pharmaceuticals, PROQUEST (Mar. 2008),
citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.549.4384&rep=rep1&type=pdf.
41
C. Ventola, Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?, 36 PHARMACY
& THERAPEUTICS 669 (Oct. 2011).
42
See Connors, supra at note 25. See also Donahue JM, Cervasco M, Rosenthal MB. A decade of
direct-to-consumer advertising of prescription drugs. NEW ENG. J. MED. 2007; 357(7):673–81.
43
Id.
44
Direct-to-consumer Advertising Under Fire, WORLD HEALTH ORG., http://www.who.int/bulletin/
volumes/87/8/09-040809/en/ (last visited May 3, 2018).
45
U.S. Health Care from a Global Perspective, COMMONWEALTH FUND, http://www.
commonwealthfund.org/publications/issue-briefs/2015/oct/us-health-care-from-a-global-perspective
(last
visited Mar. 26, 2018).
40
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conditions effectively treated through diet and exercise. 46 Marcia Angell,
former editor-in-chief of The New England Journal of Medicine disputes
pharmaceutical companies’ arguments that they need to boost profits to fund
their research. She explains how these ads are “designed to convince people
that they need pills… that happen to be more expensive” (i.e., typically those
just entering the market). 47 When consumers go to see their physician, their
requests for specific medications they have seen advertised are likely to be
honored. Doctors do not want to lose patients, and they need to move quickly.
Given expectations to see greater numbers of patients, it may be easier and
faster to write a prescription than to discuss alternatives. Consumers have also
started to expect easy, passive medication-based solutions to health concerns,
becoming less interested in discussing other options (e.g., diet, lifestyle
changes) that may be less convenient, but better for their long-term health.
Between 1999-2012 there were significant increases in adult prescription
drugs: from 51% in 1999-2000 to 59% in 2011-2012. During the same time,
the prevalence of polypharmacy (use of multiple drugs to treat a single
ailment/condition) also increased from 8.2% to 15%. 48
One study showed that people who regard DTCPA positively or neutrally
may be more vulnerable to ad messaging. Promotion-focused ads that highlight
positive health outcomes are favorable to individualistic-oriented persons
whereas prevention-focused ads that underscore negative health outcomes (of
not taking a drug) are favored by interdependent-oriented persons. 49 When an
ad’s focus matches their personal orientation, viewers are more likely to
conclude a causal connection between taking the pharmaceutical and achieving
the desirable lifestyle depicted in the ad. Furthermore, another study noted that
the motivation for taking a drug (i.e., to live a desirable lifestyle versus to
avoid pain or negative outcomes) was predominant and repeatedly reinforced
within ads while risk information was presented only once. 50 Doctors are also
influenced, led to prescribe name brand drugs, which may not be better than
generic alternatives.

46

See Ventola, supra at note 29.
Interview:
Marcia
Angell,
GPB:
FRONTLINE
(June
19,
2003),
https://www.pbs.org/wgbh/pages/frontline/shows/other/interviews/angell.html.
48
Elizabeth Kantor et al., Trends in Prescription Drug Use among Adults in the United States from
1999–2012, 314 JAMA 1818 (2015).
49
Nithima Sumpradit et al., “Give Me Happiness” or “Take Away My Pain”: Explaining consumer
responses to prescription drug advertising, 2 COGENT BUS. & MGMT. 1 (2015).
50
N. Sumpradit et al., A Cross-Media Content Analysis of Motivational Themes In Direct-ToConsumer Prescription Drug Advertising, 26(1) CLINICAL THERAPEUTICS 135 (2004).
47
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In probing the contours of this issue, we must consider whether consumers
experience the benefits defendants claim that DTCPAs provide. If, for
instance, a consumer suffers a psychiatric or neurological illness that can
impair their decision making capacity, they may be at risk of undue influence
from these ads. 51 Yet, one study found that 18% of the 50 drugs advertised
most assiduously in the U.S. were medications used to treat these kinds of
disorders. 52
One physician described how helpful conversations between patient and
doctor, which pharmaceutical ads supposedly prompt, are not helpful when
they hijack precious time in an already brief encounter. 53 He explained that he
wants to focus on what is most relevant and beneficial for his patients’ health,
adding: “If I have to spend my time fending off marketing for a condition you
don’t have or a drug that’s of no possible benefit to you, our time hasn’t been
used productively.” 54 The medical community has shared its belief that
DTCPA creates an inappropriate demand for medications and/or a demand for
inappropriate medications. 55
The Protecting Americans from Drug Marketing Act was introduced in
2009, a bill designed to encourage companies to focus on developing new
medicines, instead of developing marketing schemes. Legislation, which would
amend the Internal Revenue Code (removing the tax deduction), is part of a
growing trend to minimize the pervasiveness of DTCPA. Policymakers have
asked for a three-year moratorium on advertising newly approved prescription
drugs to consumers. Again, the AMA called for a ban on this form of
promotion, with support from a variety of stakeholder groups. But efforts to
push for a ban have stalled, given free-speech arguments made by the powerful
drug lobby and assertions that such ads provide valuable information to
patients about treatment options. Now moving to explore other aspects of the
relationship between Big Pharma and the U.S. government, we can see how
transactional reciprocity appears to fuel how legislation is cultivated and
imposed.

51
Matthew Hollon, Direct-to-consumer marketing of prescription drugs: a current perspective for
neurologists and psychiatrists, 18 CNS DRUGS 69 (2004).
52
Id.
53
John Schumann, Those TV Drug Ads Distract Us From The Medical Care We Need, NPR (Apr. 29,
2017, 5:00 AM), https://www.npr.org/sections/health-shots/2017/04/29/525877472/those-tv-drug-ads-distractus-from-the-medical-care-we-need.
54
Id.
55
Id. at 1098 (quoting from Prescription Drug Advertising Direct to the Consumer, 88 PEDIATRICS 174,
175 (1991)).
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III. GOVERNMENT REGULATION
Government regulation is designed to ensure that businesses serve the
public good, not just a fiduciary duty to their shareholders. But it is debatable
if, when, and how these regulatory efforts effectively serve the public. Looking
back, the 1940s, known as the “antibiotic era,” prompted a robust period for
the discovery and development of pharmaceutical products. This has since
evolved into an expensive, time-consuming, cumbersome, and bureaucratic
process. 56 With the Thalidomide scandal in 1961, the medical community was
shocked to learn that a drug being given to pregnant women caused serious
birth defects. This prompted activists and stakeholder groups to take action,
demanding a regulatory response. 57 This particular event triggered a
government reassessment of government controls. New regulations were
imposed to require efficacy, purity, and safety—greatly increasing research
and development (R&D) costs, particularly in the area of clinical testing. An
unintended consequence was that these enhanced regulations were deemed as
barriers to market entry, providing impetus to drive the pharmaceutical
industry’s consolidation. 58
Today, the pharmaceutical industry contributes heavily to the FDA’s
annual budget. Back in 1992, the Prescription Drug User Fee Act (PDUFA)
passed, making it the law for pharmaceutical companies to pay the FDA to
review their applications for drug approvals. In response to a lethargic and
burdensome process, this law was supposed to enable the FDA to work more
efficiently and effectively, having more resources to conduct rigorous and
timely reviews. In return, pharmaceutical firms would be able to send their
products through the regulatory pipeline faster, and patients would receive new
and potentially life-saving drugs more quickly. While the intent seemed to
serve the greater good, many argued that PDUFA put the FDA into the pockets
of the drug industry. 59 Avalere Health explored and reported how much
pharma companies have actually paid the FDA through PDFUA, adding up the
wide variety of fees collected for different types of applications (e.g., for each
56

S. Projan, Why is Big Pharma Getting Out of Antibacterial Drug Discovery?, 6(5) CURRENT OPINION
427 (2003).
57
Annas, George J., and Sherman Elias. “Thalidomide and the Titanic: Reconstructing the Technology
Tragedies of the Twentieth Century.”Health Law and Ethics 89 (1999): 98–101. Retrieved from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508516/.
58
Taylor, D. (2015). The pharmaceutical industry and the future of drug development. Pharmaceuticals
in the Environment, 1-33. DOI: 10.1039/9781782622345-00001 eISBN:978-1-78262-234-5.
59
Ramsey, L., & Friedman, L.F. (2016). The government agency in charge of approving drugs gets a
surprising amount of money from the companies that make them. Business Insider, August, 17. Retrieved
from: http://www.businessinsider.com/fda-user-fees-from-pharmaceutical-companies-2016-8.
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prescription drug application with clinical data, the fee in 2016 was over $2
million). This report found that since PDUFA was passed in 1992, pharma
companies have contributed $7.67 billion to the federal agency’s coffers. 60
This creates a interconnectedness between the two entities: a marriage between
Big Pharma and the government can potentially blur the intent of government
regulation and the role that it plays in protecting citizens.
Although interest groups have emerged to represent the rights of
companies and patients alike (e.g., pharmaceutical manufacturers,
governmental regulatory authorities, patent officers, academic and clinical
researchers, attorneys, and political action committees [PACs]). With huge
profits and a thousand paid lobbyists, Big Pharma often gains leverage in how
legislation is crafted and/or abandoned. From 1998 to 2014, Big Pharma spent
nearly $3 billion on lobbying, drowning out the voices of consumers and the
interest groups that try to represent them. 61 While some stakeholder-driven
activist groups, like Patients for Affordable Drugs, work to represent the voice
of constituents, a number of powerful groups that claim to represent patient
advocacy are tainted by special interest biases. One study shows that nearly all
patient advocacy groups are manipulated or captured by the drug industry; over
80% of these groups take money from Big Pharma. 62
The Project on Government Oversight (POGO) reports that at least 39 of
42 patient advocacy groups who participated in discussions with the FDA over
agency review processes for prescription drugs received funding from
pharmaceutical companies. 63 Additionally, at least 15 advocacy groups have
representatives of drug or biotechnology companies on their governing boards.
Congress recently passed the 21st Century Cures Act in 2016, authorizing $6.3
billion 64 in federal funding and weakening the FDA’s approval process. 65 Over

60
Woollett, J.J. (2016). FDA has received $7.67 billion from manufacturers to fund drug review.
Retrieved
from:
http://avalere.com/expertise/life-sciences/insights/fda-has-received-7.67-billion-frommanufactures-to-fund-drug-review.
61
Senate Office of Public Records data (2017). Pharmaceuticals/Health Products. Industry Summary,
2017. Open Secrets. Center for Responsive Politics. Retrieved from https://www.opensecrets.org/lobby/
indusclient.php?id=h04.
62
Thomas, K. (March 1, 2017). More than 80 Percent of Patient Groups Accept Drug Industry Funds,
Study Shows. New York Times. Retrieved from: https://www.nytimes.com/2017/03/01/health/patient-groupsdrug-industry-money.html.
63
David Hilzenrath, In FDA Meetings, “Voice” of the Patient Often Funded by Drug Companies, POGO
(Dec. 1, 2016), http://www.pogo.org/our-work/reports/2016/in-fda-meetings-voice-of-the-patient-oftenfunded-by-drug-companies.html.
64
Jennifer Steinhauer & Sabrina Tavernise, $6.3 Billion Measure Aims to Cure Ailing Health Care
Policies, N.Y. TIMES (Nov. 28, 2016) https://www.nytimes.com/2016/11/28/us/politics/congress-cures-cancermoonshot-alzheimers.html.
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1,400 lobbyists worked on the bill, which served as a major financial boon to
the drug and medical device industries. While patient advocacy groups were
engaged, many were not independent. For example, the National Health
Council, a group that calls itself The United Patient Voice, has advocated
before the FDA for faster drug approvals. Members of its board of directors
include leaders from two of the main trade groups for the drug industry—
Pharmaceutical Research and Manufacturers of America (PhRMA), and
Biotechnology Innovation Organization (BIO)—along with executives from
drug companies Sanofi, Johnson & Johnson, and Alkermes. PhRMA gave the
National Health Council $1.2 million in 2014; in all, 77% of its funding came
from the pharmaceutical and biotech industries, according to POGO. 66 The
United Patient Voice Policy Action Team also has a PhMRA representative on
it, along with an employee of Johnson & Johnson. 67
According to reports by nonprofit MapLight, drug companies poured more
than $70 million into fighting California’s Proposition 61, intended to limit the
prices state agencies pay for prescription drugs. 68 The industry often backs
legislators who favor their shareholder-driven approach. For example, Big
PhRMA spent $7 million in 2016 for their “Go Boldly” ad campaign, giving
millions to politicians who were up for election in both parties in dozens of
states. 69 The drug companies lavished more than $2 million on scores of
groups representing patients with various diseases—many of them dealing with
high drug costs. The trade group PhRMA is also known for hiring former
government employees, who are connected to those in political office. 70 Using
these relationships to pursue industry goals, Big Pharma maintains a significant
65
H.R.34–21st Century Cures Act114th Congress (2015–2016). Retrieved from: https://www.
congress.gov/bill/114th-congress/house-bill/34/.
66
New POGO Investigation: FDA and Patient Groups Addicted to Drug Industry, POGO (Dec. 1,
2016), http://www.pogo.org/about/press-room/releases/2016/new-pogo-investigation-fda-and-patient-groupsaddicted-to-drug-industry.html?print=t.
67
David Dayen, New Report Exposes “Patient Advocacy” Groups as a Big Pharma Scam, THE
INTERCEPT (Dec. 1, 2016, 2:12 PM), https://theintercept.com/2016/12/01/new-report-exposes-patientadvocacy-groups-as-a-big-pharma-scam/.
68
Seipel, J. (2016, August 11). Election 2016: Big Pharma’s $70 million tops California campaign
contributions. The Mercury News. Retrieved from: http://www.mercurynews.com/2016/07/11/election-2016big-pharmas-70-million-tops-california-campaign-contributions/.
69
Jay Hancock, In Election Year, Drug Industry Spent Big to Temper Talk about High Drug Prices, NPR
(Dec. 18, 2017, 7:00 AM), https://www.npr.org/sections/health-shots/2017/12/18/571206699/in-election-yeardrug-industry-spent-big-to-temper-talk-about-high-drug-prices.
70
See, e.g., Hiring Former Federal Government Employees as Lobbyists, CAPLIN & DRYSDALE (June 11,
2009),
http://www.capdale.com/Closing-the-Revolving-Door-Post-Employment-Lobbying-RestrictionsFollowing-HLOGA-and-Obamas-Executive-Order-on-Ethics-06-10-2009; Jay Hancock & Shefali Luthra,
States take on drug prices; Big Pharma takes on states, NBC NEWS (Jan. 30, 2018, 6:33),
https://www.nbcnews.com/health/health-care/states-take-drug-prices-big-pharma-takes-states-n842886.
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advantage that can be used to override stakeholder interests. Such integrated
forms of control contribute to the high cost and limited availability of certain
drugs. U.S. citizens pay more than those of any other country for their
pharmaceuticals. 71 U.S. prices for major brand-name drugs spiked 127%
between 2008-2014. 72 This is in comparison with an 11% rise in a shopping
cart of common household goods (according to Express Scripts, the largest
U.S. manager of drug plans). 73 Big Pharma often points to extensive
development costs to justifying its pricing strategies. However, this
explanation merits additional consideration.
Aiming to improve American-owned businesses in global markets,
Congress enacted a series of laws designed to speed up tax-supported research
on new products. One of these laws, the Bayh-Dole Act of 1980, 74 enabled
universities and small businesses to patent and/or license any discoveries from
their tax-funded medical research sponsored by the National Institutes of
Health (NIH). Prior to this law, taxpayer-financed discoveries belonged to the
public domain (i.e., new drugs were available to any company that wanted
them). As the result of this legislation, universities that carried out NIHsponsored work could charge royalties, providing income for non-profit
institutions. Legislation was also passed that allowed the NIH to enter into
deals with drug companies, transferring NIH discoveries directly to industry.
This wave of legislation provided a huge boost to the nascent
biotechnology industry, thereby paving the way for a tremendous buildup of
Big Pharma. Small biotech operations, many of them founded by university
researchers, proliferated. Much of the burden for the initial phases of drug
development shifted from Big Pharma to smaller firms. The smaller firms
worked to secure deals with Big Pharma, who would then take over the
marketing of these discoveries and some level of ownership. 75 When a patent
held by a university or a small biotech company is licensed to a
pharmaceutical, Big Pharma reaps huge rewards. Laws have evolved so that
drug companies can lean upon other firms to perform a great deal of their
R&D. This has enabled them to shift some of the creation and testing of new
71
Ben Hirschler, Exclusive - Transatlantic Divide: How U.S. Pays Three Times More For Drugs,
REUTERS (OCT. 12, 2015, 10:30 AM), https://www.reuters.com/article/us-pharmaceuticals-usa-comparison/
exclusive-transatlantic-divide-how-u-s-pays-three-times-more-for-drugs-idUSKCN0S61KU20151012.
72
Ben Hirschler, How the U.S. Pays 3 Times More for Drugs, SCI. AM., https://www.
scientificamerican.com/article/how-the-u-s-pays-3-times-more-for-drugs/ (last accessed May 3, 2018).
73
Id.
74
P.L. 96-517, H.R.6933, 96th Cong. (1979–1980)
75
Jennifer Alsiver, Big Pharma Innovation in Small Places, (May 13, 2016),
http://fortune.com/2016/05/13/big-pharma-biotech-startups/.
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drugs onto external operations. 76 Drug companies license a third of their
brands from universities or small biotech operations, reflecting the irony that
very small ventures drive a large part of Big Pharma’s innovation. 77 According
to HBM Partners, a healthcare investing firm, a vast majority of drugs
originate in smaller operations—64% of them in 2015. 78
Costs of bringing a drug to market are uncertain, vague, and often
unverifiable. Gaining market approval for the development of a new medicine
is an arduous process, easily taking over a decade. Some estimates suggest that
bringing a drug to market costs in the neighborhood of $2.6 million, according
to a study by the Tufts Center for the Study of Drug Development. 79 To
encourage drug development in the U.S., regulatory laws permit
pharmaceutical firms to set their own pricing and provide protections that are
tantamount to limiting free-market competition. 80 Other countries set a limit on
what firms can charge based on the benefit of each drug. In theory, it seems
prudent to ensure that pharmaceuticals can recoup some of their losses, so they
will continue to invest in risk-intensive choices that benefit those in need.
Drugs with very small markets present particularly high investment risks.
Some drugs do not make it to market. Once a drug is approved, determining a
reasonable profit remains controversial.
Part of the problem is the number of stakeholders in the system, including
insurers, pharmacy benefit managers, pharmacies, and wholesalers, all of
whom net profit from the sale of prescription drugs. While manufacturers bear
the burden of drug production expenses they also keep the majority of the
profit. To illustrate, of every $100 spent on prescription drugs by consumers
(i.e., patients), $58 is received by the manufacturer, of which $17 is spent on
drug production, $15 is kept as profit, and $26 is utilized for other
expenditures, such as marketing and R&D. 81 Total net profit on a $100
expenditure is $23, of which $15 goes to manufacturers, $3 to insurers, $3 to
76

Jerry Avorn, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (2005).
Jennier Alsiver, Big Pharma Innovation in Small Places, Fortune.com (May 13, 2016),
thttp://fortune.com/2016/05/13/big-pharma-biotech-startups/.
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Id.
79
Sandra Peters, Cost to Develop and Win Marketing Approval for a New Drug is $2.6 Billion, TUFTS
CENTER FOR THE STUDY OF DRUG DEVELOPMENT (Nov. 22, 2014), https://www.americanentrepreneurship.
com/press-releases/cost-to-develop-and-win-marketing-approval-for-a-new-drug-is-26-billion.html.
80
U.S. Health Policy Gateway, Pharmaceutical regulation, (Apr. 14, 2018), http://
ushealthpolicygateway.com/vii-key-policy-issues-regulation-and-reform/l-health-care-regulation/
pharmaceutical-regulation/.
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Neeraj Sood Et Al., The Flow of Money Through The Pharmaceutical Distribution System, USC
SCHAEFFER CENTER (June 13, 2017), http://healthpolicy.usc.edu/documents/USC%20Schaeffer_Flow%
20of%20Money_2017.pdf.
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pharmacies, and $2 to pharmacy benefit managers. 82 While these figures vary,
depending on whether the purchased drugs are generic or branded, only 17% of
the cost is estimated to fund drug development, while 23% of the total
purchase price is absorbed by stakeholders as profit. 83
The unintended consequence of the money flow throughout the distribution
system and supply chain is that pharmaceutical firms can corner the market on
a particular drug and then drive up the price. It is arguable that the prices drug
companies charge could be cut dramatically without threatening future
investments in R&D or eroding future profits. Research and development is a
relatively small part of Big Pharma’s budget, especially in comparison to the
amount spent on sales and marketing. For every dollar spent on R&D, nineteen
dollars go to marketing. 84 Said differently, 9 out of 10 of the biggest
pharmaceutical companies actually spend more on advertising than on R&D,
according to The Washington Post. 85 Sixteen drugs accounted for more than
$100 million each in spending last year, with the most advertised drug being
arthritis treatment Humira, at $357 million, according to the health news site
Stat. 86 The average stock return over the last decade for the 10 biggest
pharmaceutical companies based on 2015 sales is 88%. 87 This statistic is
skewed, impacted by the unseemly returns of over 480% during the period for
Gilead. 88
Given its mega-profits, Big Pharma has become known for its ability to
wield political and social influence over its stakeholders, including the federal
government and its agencies, healthcare systems, insurance firms, medical
practitioners and administrators, hospitals, and consumers. Big Pharma has
become one of the most profitable industries in the U.S., with 25-30% net
margin profits (2016), rivaled largely by accounting, legal, and investment

82

Id.
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Keith Speights, 12 Big Pharma Stats that will Blow you Away, The Motely Fool, (Jul. 31, 2016),
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services, along with leasing operations and dentists (in 2017). 89 The industry
has so much power that it has actually shaped how Western medicine and its
citizens think about their health and well-being. Pharmaceutical companies
strategically produce what increases earnings for their shareholders. But when
the zeal for profit becomes an overriding goal, the interests of non-shareholder
stakeholders are ignored, as depicted in this 2015 email from Martin Shkreli,
former CEO of Turing Pharmaceuticals, maker of Daraprim:
$1bn here we come. I think it will be huge. We raised the price from
$1,700 per bottle to $75,000. So 5,000 paying bottles at the new price
is $375,000,000 . . . almost all of it is profit and I think we will get 3
years of that or more. Should be a very handsome investment for all
of us. Let’s all cross our fingers that the estimates are accurate. 90

Reports about how Turing acquired the full rights to a 60-year-old generic
drug and then promptly raised its price 5000% outline how Shkreli’s bold
projections complemented his strategy. 91 The drug treats toxoplasmosis, a
parasitic infection that is particularly perilous for HIV/AIDS patients. Turing’s
documents were made public when participants on the House Government
Reform and Oversight Committee investigated citizen outrage. Their inquiry
confirmed the stark and grotesque reality: Turing had raised the price of
Daraprim exorbitantly because it could do so—legally. In addition to windfall
profits, the company reaped stakeholder backlash that forced Shkreli out.
Amidst protests and investigations, fraud charges were brought against Shkreli
and he was sentenced to a 7-year prison sentence in 2018. 92 His expulsion,
however, provided no relief to patients in desperate need of the drug.
Unfortunately, such unseemly pricing strategies are not confined to one
rouge greedy executive or a few unethical firms. Pricing decisions are

89
Mary Ellen Biery, These Are The 10 Most Profitable Industries in 2017, FORBES (Aug. 6, 2017),
https://www.forbes.com/sites/sageworks/2017/08/06/these-are-the-10-most-profitable-industries/#632c67c
715f0.
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3, 2016), http://money.cnn.com/2016/02/03/news/shkreli-turing-daraprim-price-house-hearing/; see also
Andrew Pollack & Mathew Goldstein, Martin Shkreli All But Gloated Over Huge Drug Price Increases,
Memos Show, N.Y. Times, (Feb. 2, 2016), https://www.nytimes.com/2016/02/03/business/drug-makerscalculated-price-increases-with-profit-in-mind-memos-show.html.
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Renae Merle, Martin Shkreli Sentenced to Seven Years in Prison for Defrauding Investors, THE
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commonly based on the desire to maximize profits. For example, in early 2015
Valeant Pharmaceuticals purchased two heart medications. Taking sole
ownership, the company subsequently hiked prices by 525% and 212%,
respectively. 93
In just one year, Valeant garnered $351 million in profits from these two
products. 94 But this success was short lived. After the U.S. Attorney’s offices
subpoenaed the company, its stock price plunged. In another case, Mylan,
maker of the EpiPen emergency remedy for anaphylaxis, paid nearly half a
billion dollars to settle a Justice Department complaint for misclassifying the
drug under Medicaid, while separately facing other legal
complaints for overcharging consumers. 95
Industry professionals argue, however, that the market for medicines is
unique. Both Turing and Valeant trade in medicines for uncommon illnesses,
so-called orphan drugs (i.e., a small user base for medicines that treat rare
diseases/disorders). Because so few patients need these drugs, there is little
incentive for others to produce them and little or no competition. Leveraging
this power, one Turing PowerPoint presentation strategically underscored the
firm’s desire to control the market:
 Drugs are typically nondiscretionary and consumers are relatively
price-insensitive.
 Typically, there is an inverse correlation between prevalence of a
disease and the annual cost of treatment.
 Exclusivity (closed distribution) creates a barrier and pricing
power. 96
Turing’s internal strategy emphasized hiding costs from patients and
avoiding fights with HIV/AIDs advocates and hospitals. But the firms that
make headlines are not the only ones raising their prices; prescription

93
Pharma and Arbitrary Drug Prices, Actuarial Outpost (Sept. 20, 2015, 7:07 PM),
http://www.actuarialoutpost.com/actuarial_discussion_forum/archive/index.php/t-299668.html.
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(May 9, 2017), https://www.reuters.com/article/us-valeant-pharm-in-results/drugmaker-valeant-raises-profitforecast-shares-spike-idUSKBN18517P?feedType=RSS&feedName=businessNews.
95
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http://money.cnn.com/2016/10/07/news/companies/epipen-mylan-465-million-fine/.
96
Jeffrey Young & Shane Ferro, Pharma bro emails reveal just how greedy drug companies can be,
THE HUFFINGTON POST (Dec. 19, 2016), http://www.huffingtonpost.com/entry/martin-shkreli-pharma-brodrug-prices_us_56b0fac5e4b0655877f75453.
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medication prices have been rising faster than inflation for years. 97 Even the
prices of generic drugs, which are supposed to provide consumers with less
expensive options, have climbed: 30% profit in 2017 (i.e., generic drugs are
now being priced to benefit shareholders over stakeholders). 98 Big Pharma
maintains that their motives are to produce additional income to advance the
science of treatment, funding not only R&D but also patient access programs
that dispense free or low-cost medicines to the uninsured and reduced copayments for certain populations. Valeant instituted patient access programs
after receiving complaints about its prices. Although a few consumers benefit
from these programs, the vast majority are hit hard by the high price of
medication.
Big Pharma has been involved in numerous billion-dollar lawsuits (see
Table 2). In recent years, pharmaceutical companies have agreed to pay over
$13 billion to resolve U.S. Department of Justice allegations of fraudulent
marketing practices, including the promotion of medicines for uses that were
not approved by the FDA. 99 Cases typically involve misbranding and off-label
marketing, giving kickbacks to physicians for prescribing and/or
recommending drugs, and strategically aligning with generic companies as a
means to keep the overall cost of drugs higher than their justified benefits. 100
Increases in the size and number of these cases contributes to the concern that
the government itself has been complicit in the illicit behavior. 101

97
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Table 2. Major Settlements between Big Pharma and the U.S. Department of
Justice (2009-13) 102
Company Name

Drug Names

Settlement

Date

GlaxoSmithKline

Paxil, Wellbutrin

$3 billion

2012

Pfizer

Bextra

$2.3 billion

2009

Johnson & Johnson

Risperdal, Invega,
Natrecor

$2.2 billion

2013

Abbott Laboratories Depakote

$1.5 billion

2012

Eli Lilly

Zyprexa

$1.4 billion

2009

Amgen

Aranesp

$762 million

2012

Sanofi-Aventis

Hyalgan

$109 million

2012

Pharmaceutical companies are undeterred by fines, legal fees, and
settlement payouts, which they seem to view as costs of doing business. The
reality is that consumers ultimately pay for government programs through their
tax dollars. Cost increases also contribute to higher insurance premiums,
higher deductibles, and decreased coverage. The U.S. is the only major market
where pharmaceutical pricing remains unregulated. Mahmud Hassan, director
of Rutgers Business School’s pharmaceutical management program, says that
stakeholders in the U.S.—patients, health insurers, and the government—pay
more for their prescribed medicines than those in countries with national health
programs, and sometimes double. 103

102
Lena Groeger, Big Pharma’s big fines, PROPUBLICA (Feb. 24, 2014), http://projects.propublica.org/
graphics/bigpharma.
103
Jeffrey Young & Shane Ferro, Pharma bro emails reveal just how greedy drug companies can be,
THE HUFFINGTON POST (Dec. 19, 2016); see also, Stephen Feller, Americans pay more than double what other
nations pay for drugs, UPI (Aug. 23, 2016), http://www.upi.com/Health_News/2016/08/23/Americans-paymore-than-double-what-other-nations-pay-for-drugs/8501471964588/.

SEKERKA_BENISHEK GALLEYFINAL

2018]

5/10/2018 12:23 PM

THICK AS THIEVES?

133

IV. THE MEDICAL COMMUNITY
Doctors, scientists, research organizations, medical journals, teaching
hospitals, and university medical schools all accept money from the
pharmaceutical industry. Medical researchers sometimes coauthor articles in
concert with Big Pharma or receive funds for ghostwriting information that
reflects certain results that may ultimately be published in medical journals.
Research conducted by scientists associated with pharmaceutical firms has
been used to promote (directly or indirectly) many drugs—including
antidepressants Paxil and Zoloft, anti-epilepsy drug Neurontin, painkiller
Vioxx, and recalled weight loss drug Fen-Phen. It is common practice for a
pharmaceutical firm to pay a medical reviewer to write a comprehensive
assessment of a new drug for a medical journal. Accounts of slanted research
have appeared in medical journals, despite claims by authors of their unbiased
scientific evaluation, separate from any financial ties to the industry. For
example, the disclosure that in 1967 the sugar industry paid Harvard scientists
to obscure a link between sugar and heart disease. 104 An unintended
consequence of this misleading information has been decades of research
examining the effects of saturated fat—rather than sugar. 105 Researchers say
that this thwarted a more thorough investigation, which has likely contributed
to an increase in the rate of heart disease in the U.S. 106
A former editor of the British Medical Journal describes how the
pharmaceutical industry can cleverly use medical journals to their own
advantage. 107 Most, including the Journal of the American Medical
Association, benefit from advertising dollars from Big Pharma. Drug
companies also sponsor clinical trials that researchers are paid to administer.
Academics and scientists conduct the research, collecting data and preparing
and analyzing the findings. Nevertheless, sponsors often keep the data, prepare
additional analyses, and report what supports their own agenda. Drug
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companies may stage-manage drug trials, revealing the outcomes that put their
products in the best light.
Doctors in the U.S. are typically required to take accredited continuing
medical education (CME) coursework. The pharmaceutical industry provides a
substantial proportion of the annual costs of CME, using this platform as a
means to market their products. 108 Drug company representatives are key
players within the U.S. healthcare delivery system, educating doctors so they
can prescribe drugs appropriately. At the same time, pharmaceutical firms train
their representatives to push the newest (often the most expensive) products. 109
As previously described, academic centers can receive royalties from Big
Pharma on any drug or technology they help to create and patent, often
underwritten with government funds. Columbia University, for example,
received nearly $790 million from licensing agreements with biotech and
pharmaceutical companies during the 17-year life of its medical school’s
patent on a method for synthesizing certain biological products. 110
In the U.S., there is one pharmaceutical sales representative for every 2.5
office-based physicians. 111 In recent years, however, some facilities have
imposed a closed-door policy, reducing this practice (by some accounts to
1:5). 112 In some cases, physicians may welcome salespeople because they
provide free samples, which they can then use for their patients. Big Pharma
claims that this practice improves patient care, fosters appropriate medication
use, and helps millions of financially struggling patients. But scholars have
countered that “sampling” is not effective in improving drug access for the
indigent, does not promote rational drug use, and raises the cost of care. 113
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Also troubling is that healthcare professionals are continuously encouraged
to resolve patients’ concerns by prescribing medications. Given the pressure to
see more patients in less time, the system pushes physicians to provide quick
prescription-driven remedies. As a result of DTCPAs, consumers’ can be
psychologically manipulated and there is a greater likelihood for doctors to
inappropriately prescribe certain drugs. 114 Pharmaceutical companies also
sponsor symposia and medical conventions, offering medical practitioners
opportunities to extend their education. These events often include free travel
and other benefits, making it difficult to be anything but favorably inclined
towards the sponsoring firms that help subsidize them. In medical schools,
preceptors, teachers, department chairs, and deans may sit on drug companies’
boards of directors. Money from Big Pharma also supports educational
programming within many medical schools and teaching hospitals. Company
reps can gain access to doctors in these settings and promote their wares. 115
This serves to reinforce a drug-intensive style of practice.
V. MOVING FORWARD
It has been a decade since Hirsch called for pharmaceutical firms to adopt a
system of corporate social responsibility. 116 He urged leaders to recognize and
protect stakeholders, prompting a shift from the bottom line model to one that
inculcates ethics and human rights. But years later, Big Pharma is still largely
driven by providing fiduciary gains to shareholders and corporate executives.
Its profound focus on self-interest places in question how much of what it does
actually benefits society. Over the past several decades, the pharmaceutical
industry has generally become a marketing machine to sell drugs that generate
the ultimate highest profit potential. As Big Pharma wields its power within the
U.S. Congress, FDA, academic medical centers, and within the medical
profession itself, patients are likely to find themselves confused, frustrated
about options, and without recourse.
More recently, consumers are now experiencing huge pricing variations for
the exact same drugs. A study in April of 2018 by Consumer Reports suggests
that pharmacies are now imposing their own price increases, without notice to
consumers. In comparing what it would cost (retail cash prices for a one-month
114
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supply of five commonly prescribed drugs, the range in prices was stunning.
All five drugs were only $66 when purchased at the online pharmacy
HealthWarehouse.com, $105 when purchased at Costco. The two highestpriced national retailers—CVS and Rite Aid—had prices closer to $900 for the
very same drugs. 117 What adds to the distressing nature of this practice is that
when a consumer uses their insurance, they may now be told that certain drugs
are no longer covered by their insurance, and shocked to see what used to be
$10 is now much more (in this cast $60) (first author personal experience at
CVS, April 1, 2018). In fact, taking this exact same prescription to another
drugstore that day (in this case, Walgreen’s), produced an approved co-pay
amount of $10 (i.e., the insurance did cover it). This lack of transparency
includes bizarre rationales by drugstores, based on whether or not they
received a coupon for the drug, from the manufacturer. At this point,
consumers literally have to shop around to find where their co-pays will be
honored and to find the best prices for their prescriptions. This may include
resorting to crossing borders, literally or via the Internet to procure cheaper
medicine. In largess, it is typically considered to be illegal for citizens to
import prescription drugs into the U.S. And the Food and Drug Administration
says:
Medicine bought from foreign sources, such as from Internet sellers,
from businesses that offer to buy foreign medicine for you, or during
trips outside the United States, may not be safe or effective. These
medicines are illegal and may present health risks, and FDA cannot
ensure the safety, efficacy and quality of medicine from these
sources. FDA cannot help consumers who have problems with
medicine obtained from outside U.S. regulation and oversight. 118

As consumers continue to navigate this opaque and continuously changing
market, the cost and complexities of drug discovery continue to increase. This
is causing Big Pharma to shift from the development of medicine that targets
short-course therapies for acute diseases to the long-term treatment of chronic
conditions. And, despite a growing clinical need, there is a disturbing lack of
investment in producing novel antibacterial agents. Drug options for treatment
of infections have become increasingly limited, as antimicrobial resistance
becomes increasingly robust. Generic antibiotics are in short supply, and the
development of new antibiotics has been severely curtailed. Only four large
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pharmaceutical companies with antibiotic research programs remained in
existence in 2002. As reported by Pew Research in 2016:
New discoveries dropped precipitously from the 1980s onward. As a
result, the development of antibiotics has declined, with new FDA
approvals for these drugs falling from 29 during the 1980s to nine in
the first decade of the 2000s. All antibiotics approved for use in
patients today are derived from a limited number of types, or classes,
of antibiotics that were discovered by the mid-1980s. This is even
more concerning than the decline of drug approvals because
resistance to one antibiotic often leads to resistance to multiple
antibiotics within the same class. Faced with poor discovery
prospects and diminishing returns on investment, major drug
companies have cut back or pulled out of antibiotic research
altogether. This has left much of the remaining discovery work to
small, “pre-revenue” companies with no products on the market and
limited budgets and R&D capacity. Most industry antibiotic
development programs are primarily focused on modifying existing
classes of drugs discovered decades ago to circumvent bacterial
resistance and better target difficult-to-treat infections. Though
essential, such incremental advances are not likely to meet the
looming public health challenge of antibiotic resistance in the long
term. 119

Pharmaceutical companies face a paradox wherein federal agencies call for
antibiotic development even as other federal agencies enact policies limiting
the appeal of that very development. 120
Critics from the medical stakeholder community claim there is insufficient
science guiding pharmaceutical business decisions and that financial incentives
go in the wrong direction. Big Pharma wants consumers to take a pill every
day for the rest of their lives. Therefore, they invest in new forms of birth
control, cholesterol blockers, and antidepressants that dominate the market.
Meanwhile, vaccines have become scarce. Big Pharma and its university
partners have been charged with paying little attention to salient issues of
public health, and focusing instead on products expected to maximize profits.
Critics underscore how Big Pharma has grossly subordinated patient needs in
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favor of its own investment returns. 121 Allen Frances, Chair of the DSM-IV
Task Force, warns that the gradual mislabeling of everyday problems as illness
has toxic implications for individuals and society: stigmatizing people,
introducing them to potentially harmful medications, misallocating medical
resources, and draining the budgets of families and the nation. Wellness has
been shifted away from our own naturally resilient and self-healing capacity,
into the hands of Big Pharma, who reap multi-billion-dollar profits at citizens’
expense. 122
Big Pharma presents a disturbing ironic reality: the industry offers lifesaving health benefits, and yet remains one of the least trusted. The reality is
that “some of the largest drug companies in the world—the one’s that we rely
on for life saving treatments—are convicted criminals.” 123 Are regulators
enablers? Or, perhaps worse still, are they complicit in questionable or
ethically unsound activities as a result of being driven by self-serving motives?
Working to untie and address this Gordian knot of interrelated profiteering and
motivated special interests will require increased stakeholder engagement and
government activism. U.S. Senator Bernie Sanders (I-VT) asserts that “people
must be prepared to stand up to powerful special interests like the
pharmaceutical industry and like Wall Street.” 124 Before taking office,
President Donald Trump said the pharmaceutical industry was “getting away
with murder,” and vowed to do something about it. 125 The reality to date,
however, is that Big Pharma has the power to continue to dictate the pricing of
drugs in the U.S., where our legal platform continues to offer incentives for
firms to extract exorbitant prices. Traditional common law remedies have not
resulted in deterrence. 126
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Despite public knowledge of Big Pharma’s self-serving practices,
pharmaceutical companies claim that their mission is to benefit people.
Reformers call for restructuring the industry itself, so that it remains grounded
in science but is genuinely motivated to provide safe and effective drugs for
the public. Accomplishing this aim will require protracted and sustained citizen
and stakeholder engagement, demonstrated via a determined commitment to
prompt reflection, informed dialogue, and bipartisan reform. To create
systemic change, fresh ideas need to be explored. One plan for tackling the
expensive limited access to drugs has emerged from the medical community.
The idea is for the U.S. federal government to buy pharmaceutical firms
outright, rather than buying the drugs themselves. 127
For example, according to the Center for Disease Control and Prevention,
Hepatitis C kills more Americans than any other infectious disease and often
leads to a need for liver transplants. 128 Gilead Sciences Inc. makes Sovaldi and
Harvoni, the two drugs that can swiftly cure this disease, but sells them at
prices so high that few can afford them (a 12-week course is $84,000). 129
States restrict their use, telling patients they are not sick enough to justify the
cost. The drugs consistently eradicate the virus, which has infected an
estimated 2.7 to 3.3 million people in America. 130 Buying the company instead
of the drugs would cut the cost of treatment by almost two-thirds. The
government could then sell the firm itself, but sustain the drug rights. Doing so
would cut the cost of treatment, stop the disease from spreading, and reduce
the number of liver transplants needed.
The idea of having the government purchase corporate shares at full price
on the open market may seem far-fetched. But it represents the kind of
transformational thinking that might help to promote deep change. Experts say
that if the federal government treated illnesses as public health issues, rather
than as Medicaid budget problems, innovative ideas like this one would be
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more likely to emerge. 131 They argue that the government needs to focus
explicitly on curing and saving patients, and to move away from reinforcing
practices such as prescription-based care and drug dependency, which benefit
the industry but harm citizens. Manufacturers and suppliers need to co-create
stakeholder codes of conduct that reduce or eliminate DTCPA and reflect
increasing efforts to support and enhance public awareness of disease
prevention and management. Executives leading Big Pharma firms must be
held accountable; liable for the misconduct they participate in, enable, or turn a
blind eye toward. Prosecutors need to be able to exact penalties that are potent
enough to affect corporate behavior, such as fines that involve garnishing 15%
of a firm’s annual profits and executive compensation and benefits. Some
suggest that Big Pharma be regulated like public utilities. 132 If the government
regulated drug pricing, as it does for electricity, it would likely prompt
competition between companies and drive prices lower, benefiting all,
including government programs.
The convergence of IT and healthcare is another path that might prompt a
shift in the Big Pharma model. Big data, apps, and mobile health are starting to
transform healthcare and diagnostics in a significant way, with Apple and
Google acting as steadfast disruptive catalysts. Medicines paired with
companion diagnostics may be an increasingly leveraged strategy to gain
market access. At present, AstraZeneca, Roche, Novartis and Sanofi are
progressing as much as 60–80% of their clinical portfolios with companion
diagnostics. 133 In the era of personalized and precision medicines, this strategy
will likely translate into medicines accompanied with apps or wearable devices
that help patients monitor key parameters and manage their diseases. How big
pharma adapts to this ‘beyond-the-pill’ model will be an interesting
development during the next decade. 134
In broader terms, academic institutions need to educate the next generation
of business leaders to view social responsibility and governance as key
components in the calculation of value and profit. It is not enough to increase
the value of corporate stock in the short term. Firms must incorporate a
stakeholder perspective, accompanied by a longer-term profit horizon. Perhaps
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policymakers can leverage insights from business protocols like “B Corp,”
where certification requires the ability of a firm to meet rigorous stances of
social and environmental performance, accountability, and transparency. 135
Big Pharma, affecting the health and welfare of every citizen, is at the
intersection of business and society. Policy and lawmakers who are free from
the influence of lobbying forces must help corral Big Pharma, toward
redirecting a reasonable portion of their profits to benefit consumers. This is
both possible and feasible via legislation that imposes stricter regulations on
DTCPA and limits drug patent extensions, as well as the reevaluation of the
learned intermediary doctrine by the judicial system. 136 How this industry
moves forward presents one of the biggest ethical challenges of the 21st
century, seeking a balance between capitalism and the corporation’s duty to its
share- and stakeholder constituents.
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